ReviewCurrent opinion in allergy and clinical immunology2026
Asthma in athletes: diagnostic challenges and management strategies.
Review in Current opinion in allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewExercise-induced bronchoconstriction (EIB) and exercise-induced asthma (EIA) are common conditions among athletes and represent an important clinical issue with potential implications for both respiratory health and athletic performance. The prevalence of asthma in athletes is higher than in the general population, likely due to the combined effects of increased ventilatory demand and environmental exposures. RECENT
findingsThe pathophysiology of EIB is multifactorial and involves osmotic and thermal mechanisms related to airway dehydration during exercise-induced hyperventilation. Although some athletes present a classical T2-high inflammatory phenotype associated with allergic sensitization, a considerable proportion develop EIB through non-T2 inflammatory pathways, including airway epithelial injury and autonomic dysregulation. SUMMARY: Diagnosis requires objective assessment through pulmonary function testing and bronchial provocation tests. Biomarkers like fractional exhaled nitric oxide (FeNO) and blood eosinophil counts can support phenotypic characterization, but they do not replace functional testing. Management in athletes follows established asthma guidelines and includes inhaled corticosteroids as the cornerstone of therapy, combined with pharmacological and non-pharmacological strategies. Considering anti-doping regulations is also essential to ensure appropriate treatment and compliance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.